Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Researchers obtain understanding of pathomechanisms underlying two age-related eye disorders

Population aging is a global phenomenon with profound medical implications. Tissue dysfunction associated with aging affects all vital organs, including the eyes.

3 Oct 2018

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.

3 Oct 2018

Hopkins gastroenterologists use endoscopic procedure to deliver therapeutic genes to the liver

Fixing or replacing faulty genes has emerged as a key to unlocking cures for numerous devastating diseases. But if the new, engineered genes can't find their way into the patient's genomic sequence, they won't help.

3 Oct 2018

Genetic variants reveal novel therapeutic targets for chronic kidney disease

The kidney does more than double or even triple duty compared to other organs - it extracts waste, balances body fluids, forms urine, regulates blood pressure, and secretes hormones.

1 Oct 2018

Insilico Medicine collaborates with MAWI to develop multi-modal biomarkers of aging

Cardiovascular disease is the leading cause of death and disability in the world. On the eve of the annual World Heart Day, September 29th, Insilico Medicine, Inc., a Rockville-based next-generation artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research announced a research collaboration agreement with MAWI, the next-generation consumer and clinical wearable company, the developer of one of the most accurate clinical-grade ECG wearable devices.

28 Sep 2018

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics.

27 Sep 2018

Antibiotic resistance in cystic fibrosis linked to decreased microbial diversity and pulmonary function

A defective gene causes thick, sticky mucus to build up in the lungs of patients with cystic fibrosis. There, it traps bacteria, causing patients to develop frequent lung infections that progressively damage these vital organs and impair patients' ability to breathe.

27 Sep 2018

Mesoblast’s MPC therapy for children featured at symposium for congenital heart disease

Mesoblast Limited today announced that Mesoblast's proprietary allogeneic mesenchymal precursor cell heart failure product candidate MPC-150-IM for use in children with hypoplastic left heart syndrome was featured at the First Cardiac Regenerative Symposium for Congenital Heart Disease in Baltimore, Maryland on the weekend.

26 Sep 2018

AmpliPhi receives positive feedback from FDA for its AB-PA01 product targeting P.aeruginosa infections

AmpliPhi Biosciences Corporation, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback, via written response, from the U.S. Food and Drug Administration regarding its development plans for AB-PA01, without the need for a Type B Pre-IND meeting.

19 Sep 2018

Researchers map 3D structure of toxic proteins used by Pseudomonas aeruginosa to trigger infection

The bacteria Pseudomonas aeruginosa can cause serious and difficult to treat infections. The infection process involves the activation of toxic substances from the bacteria by a common protein in our cells.

17 Sep 2018

Study reveals long-term safety, efficacy of Ofev in patients with idiopathic pulmonary fibrosis

Results from INPULSIS-ON, published today in Lancet Respiratory Medicine, provide insights into the long-term safety, efficacy, and tolerability of Ofev (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF).

17 Sep 2018

Short-term psychotherapy improves mental health of women caring for children with chronic conditions

Brief cognitive behavioral therapy significantly improved the mental health of women overwhelmed by caring for children with severe chronic health conditions, researchers at the University of Louisville have found.

14 Sep 2018

Previously unknown virus acts as 'driver' for interstitial nephropathy

An international research team led by Wolfgang Weninger, who has been Head of MedUni Vienna's Department of Dermatology since 1 September, has discovered a previously unknown virus that acts as a "driver" for certain kidney diseases (interstitial nephropathy).

14 Sep 2018

Caspase-2 enzyme inhibitor could provide effective way to stop aggressive fatty liver disease

Researchers at University of California San Diego School of Medicine have discovered using mice and human clinical specimens, that caspase-2, a protein-cleaving enzyme, is a critical driver of non-alcoholic steatohepatitis, a chronic and aggressive liver condition.

14 Sep 2018

Researchers identify mechanism that could make pathogens more susceptible to antibiotics

Scientists at the Research Institute of the McGill University Health Centre (RI-MUHC) have identified new means of fighting drug-tolerant bacteria, a growing global threat as menacing as drug-resistant microbes.

14 Sep 2018

New test to predict advanced fibrosis in people with NAFLD

A new test may soon be available to predict advanced fibrosis in people with non-alcoholic fatty liver disease.

12 Sep 2018

New research on molecular mechanistic understanding of drug delivery and drug delivery systems

Today, Insilico Medicine, Inc., a Rockville-based next-generation artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research announces the publication of a new research paper "Entangled Conditional Adversarial Autoencoder for de-novo Drug Discovery" in Molecular Pharmaceutics, the leading American Chemical Society journal covering research on the molecular mechanistic understanding of drug delivery and drug delivery systems

12 Sep 2018

Fibrosis News and Research

Further Reading

Researchers obtain understanding of pathomechanisms underlying two age-related eye disorders

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Hopkins gastroenterologists use endoscopic procedure to deliver therapeutic genes to the liver

Genetic variants reveal novel therapeutic targets for chronic kidney disease

Insilico Medicine collaborates with MAWI to develop multi-modal biomarkers of aging

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Antibiotic resistance in cystic fibrosis linked to decreased microbial diversity and pulmonary function

Mesoblast’s MPC therapy for children featured at symposium for congenital heart disease

AmpliPhi receives positive feedback from FDA for its AB-PA01 product targeting P.aeruginosa infections

Researchers map 3D structure of toxic proteins used by Pseudomonas aeruginosa to trigger infection

Study reveals long-term safety, efficacy of Ofev in patients with idiopathic pulmonary fibrosis

Short-term psychotherapy improves mental health of women caring for children with chronic conditions

Previously unknown virus acts as 'driver' for interstitial nephropathy

Caspase-2 enzyme inhibitor could provide effective way to stop aggressive fatty liver disease

Researchers identify mechanism that could make pathogens more susceptible to antibiotics

New test to predict advanced fibrosis in people with NAFLD

New research on molecular mechanistic understanding of drug delivery and drug delivery systems

Inhaled form of high blood pressure drug has potential to treat anxiety, pain

Cedars-Sinai receives $12 million from NIH to investigate deadly lung conditions

Mouse study suggests new therapeutic approach to treat heart failure

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News